{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":19,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":19,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"31c98ffb0e4d","filters":{"venue":"Liver Cancer"}},"results":[{"id":"W3173725877","doi":"10.1159/000513486","title":"Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study","year":2021,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Bevacizumab; Medicine; Internal medicine; Hazard ratio; Sorafenib; Hepatocellular carcinoma; Gastroenterology; Progression-free survival; Population; Phases of clinical research; Oncology; Clinical endpoint; Randomized controlled trial; Clinical trial; Confidence interval; Cancer; Chemotherapy; Nivolumab; Immunotherapy","authors":[{"name":"Shukui Qin","is_ca":false},{"name":"Zhenggang Ren","is_ca":false},{"name":"Yin‐Hsun Feng","is_ca":false},{"name":"Thomas Yau","is_ca":false},{"name":"Baocheng Wang","is_ca":false},{"name":"Haitao Zhao","is_ca":false},{"name":"Yuxian Bai","is_ca":false},{"name":"Shanzhi Gu","is_ca":false},{"name":"Lindong Li","is_ca":false},{"name":"Sairy Hernandez","is_ca":false},{"name":"Derek-Zhen Xu","is_ca":false},{"name":"Sohail Mulla","is_ca":true},{"name":"Yifan Wang","is_ca":false},{"name":"Hui Shao","is_ca":false},{"name":"Ann‐Lii Cheng","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1069567075284236,"gpt":0.3480448685584838,"spread":0.2410881610300601,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002066392,0.001069669,0.001993635,0.0002978996,0.000316749,0.0005023197,0.0007344839,0.000757555,0.002016559],"category_scores_gemma":[0.001096497,0.0003582928,0.001763876,0.0004274315,0.0006872237,0.0004987398,0.0003689356,0.001385242,0.000371874],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001120335,"about_ca_system_score_gemma":0.002396779,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002487955,"about_ca_topic_score_gemma":0.006625447,"domain_scores_codex":[0.9995542,0.0002139195,0.00002942674,0.00007768752,0.00005680755,0.00006791734],"domain_scores_gemma":[0.9992017,0.0001143211,0.0002009546,0.0000815719,0.00007491536,0.0003265665],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.928539,0.0109366,0.01428023,0.0006992671,0.003644284,0.0001268874,0.0002460595,0.0007816195,0.006558606,0.0001073072,0.001634795,0.03244531],"study_design_scores_gemma":[0.7974893,0.1423397,0.05211477,0.0000473672,0.003189948,0.0001313805,0.00009895048,0.001319332,0.001221199,0.0001941451,0.00180251,0.00005130703],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971781,0.0008947848,0.0001186907,0.0002189,0.00003864475,0.0006839544,0.0003651895,0.00002069593,0.0004810745],"genre_scores_gemma":[0.9958825,0.0006178578,0.0003596602,0.0005725253,0.00008450017,0.0008875394,0.000980798,0.000007161202,0.000607497],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002487955,"threshold_uncertainty_score":0.01092821,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4310183164","doi":"10.1159/000528272","title":"IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study","year":2022,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Roche (Canada)","funders":"Chugai Pharmaceutical; F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Sorafenib; Bevacizumab; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Internal medicine; Hazard ratio; Oncology; Liver cancer; Cancer; Phases of clinical research; Gastroenterology; Confidence interval; Chemotherapy; Nivolumab; Immunotherapy","authors":[{"name":"Masatoshi Kudo","is_ca":false},{"name":"Richard S. Finn","is_ca":false},{"name":"Peter R. Galle","is_ca":false},{"name":"Andrew X. Zhu","is_ca":false},{"name":"Michel Ducreux","is_ca":false},{"name":"Ann‐Lii Cheng","is_ca":false},{"name":"Masafumi Ikeda","is_ca":false},{"name":"Kaoru Tsuchiya","is_ca":false},{"name":"Kenichi Aoki","is_ca":false},{"name":"Jing Jia","is_ca":true},{"name":"Riccardo Lencioni","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06051174997819984,"gpt":0.2949862541609207,"spread":0.2344745041827209,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003344452,0.0009010899,0.001566201,0.0003239188,0.0001793731,0.000994458,0.0007400393,0.0006122946,0.001732347],"category_scores_gemma":[0.001895525,0.0004426027,0.00239457,0.0003355182,0.0004791543,0.0006745421,0.0004256689,0.001651599,0.0004933018],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000953678,"about_ca_system_score_gemma":0.001064719,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005260748,"about_ca_topic_score_gemma":0.001572053,"domain_scores_codex":[0.9988417,0.0007761745,0.0000640716,0.0001350837,0.00009267935,0.00009031606],"domain_scores_gemma":[0.9986256,0.0003214227,0.0004434824,0.0001193087,0.0000961781,0.0003939637],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9063448,0.01218255,0.01745506,0.0005785669,0.004056783,0.000107621,0.0001512854,0.001722483,0.01002335,0.0001251178,0.001561293,0.04569114],"study_design_scores_gemma":[0.5474781,0.3766801,0.06389563,0.00007872999,0.003157036,0.0003274144,0.0000856793,0.00315738,0.002750948,0.0001990633,0.002132975,0.00005687651],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956157,0.002091164,0.0003113906,0.0002191141,0.00003725541,0.0004248618,0.0005458057,0.00003757369,0.0007171386],"genre_scores_gemma":[0.9966354,0.0005364902,0.0005243206,0.0002687312,0.00006208057,0.000382223,0.001157906,0.00001087466,0.0004220627],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003344452,"threshold_uncertainty_score":0.01768732,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2559460526","doi":"10.1159/000449346","title":"Hepatocellular Carcinoma: The Role of Interventional Oncology","year":2016,"lang":"en","type":"review","venue":"Liver Cancer","topic":"Microbial Inactivation Methods","field":"Biochemistry, Genetics and Molecular Biology","cited_by":60,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Hepatocellular carcinoma; Medicine; Liver transplantation; Incidence (geometry); Surgical resection; Internal medicine; Oncology; Transplantation; General surgery","authors":[{"name":"Matteo Donadon","is_ca":false},{"name":"Luigi Solbiati","is_ca":false},{"name":"Laura A. Dawson","is_ca":true},{"name":"Aisling Barry","is_ca":true},{"name":"Gonzalo Sapisochín","is_ca":true},{"name":"Paul D. Greig","is_ca":true},{"name":"Shuichiro Shiina","is_ca":false},{"name":"Andrea Fontana","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04764116408169632,"gpt":0.3697047981926722,"spread":0.3220636341109759,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006459536,0.0005445819,0.0007474155,0.001524692,0.0002853171,0.0009955217,0.0004779789,0.00100956,0.002636046],"category_scores_gemma":[0.0008821191,0.0001279073,0.0003749084,0.001254943,0.0005985116,0.001317721,0.0005532622,0.001504967,0.0009735228],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006090379,"about_ca_system_score_gemma":0.001199286,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008137651,"about_ca_topic_score_gemma":0.001152255,"domain_scores_codex":[0.9997919,0.00005480152,0.00002793459,0.00003368119,0.00007275686,0.00001900334],"domain_scores_gemma":[0.9995641,0.0002250589,0.00004905771,0.00001322356,0.0001134206,0.00003506468],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000352784,0.00003025593,0.000290971,0.008285784,0.00004938247,0.0003076134,0.00008391578,0.0002375097,0.0006898897,0.006269479,0.02671947,0.9570004],"study_design_scores_gemma":[0.000008094335,0.00005538679,0.0007162701,0.003958865,0.00006796436,0.003106703,0.00009847592,0.00008064635,0.0003152775,0.003260066,0.9883158,0.00001631092],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00009031815,0.9978051,0.0001165542,0.0007573852,0.0002463828,0.000001812968,0.000005773114,0.000005394499,0.0009712705],"genre_scores_gemma":[0.001155137,0.9975304,0.0001709571,0.0003078035,0.0004403398,0.000003276623,0.00001077423,0.000001440461,0.0003797468],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002636046,"threshold_uncertainty_score":0.008818448,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4323307162","doi":"10.1159/000529996","title":"Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study","year":2023,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Roche (Canada)","funders":"Chugai Pharmaceutical; F. Hoffmann-La Roche","keywords":"Bevacizumab; Medicine; Atezolizumab; Sorafenib; Internal medicine; Hepatocellular carcinoma; Liver function; Gastroenterology; Population; Post-hoc analysis; Oncology; Tolerability; Clinical endpoint; Surgery; Randomized controlled trial; Adverse effect; Cancer; Chemotherapy; Nivolumab","authors":[{"name":"Masatoshi Kudo","is_ca":false},{"name":"Richard S. Finn","is_ca":false},{"name":"Ann‐Lii Cheng","is_ca":false},{"name":"Andrew X. Zhu","is_ca":false},{"name":"Michel Ducreux","is_ca":false},{"name":"Peter R. Galle","is_ca":false},{"name":"Naoya Sakamoto","is_ca":false},{"name":"Naoya Kato","is_ca":false},{"name":"Michitaka Nakano","is_ca":false},{"name":"Jing Jia","is_ca":true},{"name":"Arndt Vogel","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09168397289620757,"gpt":0.3275482401496349,"spread":0.2358642672534274,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006293906,0.001699345,0.003157146,0.0003266509,0.0002184286,0.00126825,0.0009383985,0.0007783303,0.00262628],"category_scores_gemma":[0.004917473,0.0005724066,0.007406606,0.0004045584,0.0005677774,0.0007959901,0.0005798339,0.002384819,0.0004336154],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001038022,"about_ca_system_score_gemma":0.001241373,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007036434,"about_ca_topic_score_gemma":0.001717134,"domain_scores_codex":[0.9965088,0.002580898,0.0001562645,0.0003532771,0.0001779103,0.0002228225],"domain_scores_gemma":[0.9962101,0.001428593,0.0009451533,0.0005262081,0.0002349316,0.0006549665],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9646084,0.00213987,0.009065394,0.0002365138,0.0108185,0.00004543018,0.00005061737,0.001342299,0.002018572,0.00005714161,0.0007180494,0.008899168],"study_design_scores_gemma":[0.5462167,0.3051417,0.1125808,0.00006965526,0.02155511,0.0002046074,0.0001117901,0.007657215,0.003551004,0.0005060774,0.002310654,0.00009468482],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950321,0.001806595,0.0006310269,0.0002826365,0.0001269312,0.0004694325,0.0009148223,0.00004457465,0.0006918991],"genre_scores_gemma":[0.9964021,0.0003438657,0.0005100992,0.0002177671,0.0001396216,0.0004177419,0.001148965,0.00002018001,0.0007997817],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006293906,"threshold_uncertainty_score":0.03328574,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3185994964","doi":"10.1159/000516490","title":"Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma","year":2021,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Eisai","keywords":"Lenvatinib; Sorafenib; Medicine; Hepatocellular carcinoma; Internal medicine; Liver function; Adverse effect; Oncology; Overall survival; Post-hoc analysis; Gastroenterology","authors":[{"name":"Arndt Vogel","is_ca":false},{"name":"Catherine Frenette","is_ca":false},{"name":"Max W. Sung","is_ca":false},{"name":"Bruno Daniele","is_ca":false},{"name":"Ari David Baron","is_ca":false},{"name":"Stephen L. Chan","is_ca":false},{"name":"Jean Frédéric Blanc","is_ca":false},{"name":"Toshiyuki Tamai","is_ca":false},{"name":"Min Ren","is_ca":false},{"name":"Howard J. Lim","is_ca":true},{"name":"Daniel H. Palmer","is_ca":false},{"name":"Yuko Takami","is_ca":false},{"name":"Masatoshi Kudo","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05933619209472887,"gpt":0.2809289060137234,"spread":0.2215927139189945,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002918689,0.0005079008,0.0005939928,0.0003213768,0.000264878,0.0006668519,0.0003700527,0.0003561163,0.001133493],"category_scores_gemma":[0.00225524,0.0002943021,0.0007501653,0.0005263115,0.0002332681,0.0004912988,0.0004751631,0.0009746631,0.000327259],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004935558,"about_ca_system_score_gemma":0.000469813,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007542289,"about_ca_topic_score_gemma":0.001354375,"domain_scores_codex":[0.9991258,0.0005070897,0.00005686302,0.000100474,0.000129154,0.00008074562],"domain_scores_gemma":[0.9980614,0.0002759185,0.0008942071,0.0001764481,0.0002115083,0.0003805374],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06016966,0.002957409,0.9122477,0.0001449325,0.001889281,0.0001294203,0.0001114403,0.0009950799,0.004288273,0.00008600581,0.00238623,0.01459463],"study_design_scores_gemma":[0.005299159,0.01431883,0.9764178,0.00001501677,0.0005747324,0.000318954,0.00006815129,0.00111238,0.0007622217,0.00007079398,0.00101693,0.00002483453],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979905,0.0004573398,0.00010463,0.0001398134,0.00001079039,0.00007393779,0.0007485377,0.00000890955,0.0004655757],"genre_scores_gemma":[0.9975652,0.0001451941,0.000138703,0.0001222255,0.00003421198,0.00008293356,0.001700946,0.000004789394,0.0002058161],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002918689,"threshold_uncertainty_score":0.0154357,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4320717208","doi":"10.1159/000529636","title":"Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial","year":2023,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Bayer Yakuhin; Chugai Pharmaceutical; Sirtex Medical; Ipsen; Servier; Ono Pharmaceutical; Eisai; Sanofi; Bayer HealthCare; Incyte; EA Pharma Co., Ltd.; Gilead Sciences; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Hepatocellular carcinoma; Term (time); Oncology; Internal medicine; Cancer; Immunotherapy; Physics","authors":[{"name":"Philippe Merle","is_ca":false},{"name":"Masatoshi Kudo","is_ca":false},{"name":"Julien Edeline","is_ca":false},{"name":"Mohamed Bouattour","is_ca":false},{"name":"Ann‐Lii Cheng","is_ca":false},{"name":"Stephen L. Chan","is_ca":false},{"name":"T.W.C. Yau","is_ca":false},{"name":"Marcelo Garrido","is_ca":false},{"name":"Jennifer J. Knox","is_ca":true},{"name":"Bruno Daniele","is_ca":false},{"name":"В. В. Бредер","is_ca":false},{"name":"Ho Yeong Lim","is_ca":false},{"name":"Sadahisa Ogasawara","is_ca":false},{"name":"Stéphane Cattan","is_ca":false},{"name":"Yee Chao","is_ca":false},{"name":"Abby B. Siegel","is_ca":false},{"name":"Iván Martínez‐Forero","is_ca":false},{"name":"Ziwen Wei","is_ca":false},{"name":"Chih-Chin Liu","is_ca":false},{"name":"Richard S. Finn","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09416067897063918,"gpt":0.321198574962859,"spread":0.2270378959922199,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005808386,0.001036542,0.001941777,0.0002344222,0.0004636275,0.001565614,0.0005478185,0.001228114,0.005205329],"category_scores_gemma":[0.00292388,0.0003305281,0.002885903,0.0004736326,0.0004345537,0.001019966,0.0005404472,0.002816143,0.001024222],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008347239,"about_ca_system_score_gemma":0.0008950172,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006758229,"about_ca_topic_score_gemma":0.001405417,"domain_scores_codex":[0.9987524,0.0006940599,0.00008681315,0.0001616534,0.0001345897,0.0001706017],"domain_scores_gemma":[0.9980258,0.0004587926,0.0006402791,0.0002566761,0.0001769521,0.0004415977],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9174783,0.002680046,0.004928156,0.00173842,0.006288311,0.0002005999,0.0001137811,0.001303925,0.004563342,0.0002230706,0.007493793,0.05298817],"study_design_scores_gemma":[0.8402644,0.08557177,0.04758469,0.0005056655,0.009712051,0.0006379948,0.00008094208,0.001107369,0.002163694,0.0008046257,0.01148153,0.00008528081],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9465497,0.03140183,0.001467703,0.001867649,0.0004627887,0.002192245,0.01021735,0.0001508174,0.005690099],"genre_scores_gemma":[0.9709599,0.006372266,0.001019735,0.002043406,0.0004464205,0.002467655,0.01393345,0.00004629873,0.002710892],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005808386,"threshold_uncertainty_score":0.03071803,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4303470808","doi":"10.1159/000527403","title":"Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety","year":2022,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"EVRAZ (Canada)","funders":"European Commission; European Federation of Pharmaceutical Industries and Associations; University of Pittsburgh","keywords":"Regorafenib; Cabozantinib; Discontinuation; Medicine; Hepatocellular carcinoma; Sorafenib; Hazard ratio; Propensity score matching; Adverse effect; Internal medicine; Oncology; Surgery; Confidence interval; Cancer; Colorectal cancer","authors":[{"name":"Philippe Merle","is_ca":false},{"name":"Masatoshi Kudo","is_ca":false},{"name":"Stanimira Krotneva","is_ca":true},{"name":"Kirhan Özgürdal","is_ca":false},{"name":"Yun Su","is_ca":false},{"name":"Irina Proskorovsky","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1111477898344688,"gpt":0.3278793606080632,"spread":0.2167315707735943,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01010008,0.001732958,0.002994132,0.0008611378,0.0002056944,0.001212832,0.001240665,0.001194742,0.009116656],"category_scores_gemma":[0.01808064,0.0005276185,0.007927529,0.0007074906,0.0006891937,0.001046238,0.001563702,0.001981184,0.000527457],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000990438,"about_ca_system_score_gemma":0.0008242823,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001446307,"about_ca_topic_score_gemma":0.001133752,"domain_scores_codex":[0.98606,0.01071441,0.0007227493,0.001103571,0.000940073,0.0004591269],"domain_scores_gemma":[0.9928087,0.004377,0.001711882,0.00057575,0.0002442459,0.0002824426],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.8052886,0.00171306,0.01994128,0.004135375,0.09074791,0.0001198754,0.0002358978,0.01196896,0.00210723,0.002309757,0.001433027,0.05999891],"study_design_scores_gemma":[0.3975382,0.2225403,0.1030889,0.001221272,0.1672144,0.0008338209,0.000451537,0.07326982,0.007035024,0.01538302,0.01106067,0.0003630552],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9648502,0.01272746,0.01023599,0.0005795989,0.0007177874,0.002154891,0.003644351,0.000159256,0.004930304],"genre_scores_gemma":[0.9921641,0.0008100961,0.00333204,0.000289244,0.000105737,0.001225763,0.001141463,0.000017984,0.0009135263],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01010008,"threshold_uncertainty_score":0.053415,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4303470795","doi":"10.1159/000526899","title":"PD-1/CTLA-4 Blockade Leads to Expansion of CD8+PD-1int TILs and Results in Tumor Remission in Experimental Liver Cancer","year":2022,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Medizinischen Hochschule Hannover; Deutsche Forschungsgemeinschaft; Government of Canada; Wilhelm Sander-Stiftung","keywords":"Blockade; CD8; Cytotoxic T cell; Medicine; Cancer research; Priming (agriculture); Tumor-infiltrating lymphocytes; Tumor microenvironment; Immunology; Nivolumab; Immunotherapy; Immune system; Biology; Internal medicine; Receptor","authors":[{"name":"Sandra Bufe","is_ca":false},{"name":"Artur Zimmermann","is_ca":false},{"name":"Sarina Ravens","is_ca":false},{"name":"Immo Prinz","is_ca":false},{"name":"Laura Elisa Buitrago‐Molina","is_ca":false},{"name":"Robert Geffers","is_ca":false},{"name":"Norman Woller","is_ca":false},{"name":"Florian Kühnel","is_ca":false},{"name":"Steven R. Talbot","is_ca":false},{"name":"Fatih Noyan","is_ca":false},{"name":"Michael P. Manns","is_ca":false},{"name":"Heiner Wedemeyer","is_ca":false},{"name":"Matthias Hardtke‐Wolenski","is_ca":false},{"name":"Elmar Jaeckel","is_ca":false},{"name":"Ana Clara Marques Davalos‐Misslitz","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02389854169721906,"gpt":0.3067304720411475,"spread":0.2828319303439285,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001468141,0.0005488503,0.0004079016,0.0003793447,0.0001494499,0.0001922163,0.0002109229,0.000222276,0.001673631],"category_scores_gemma":[0.0001002402,0.0001485216,0.000273736,0.000153233,0.0002845236,0.0002214035,0.0001676707,0.001117551,0.0003466435],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003145774,"about_ca_system_score_gemma":0.0002653464,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004498318,"about_ca_topic_score_gemma":0.0005822884,"domain_scores_codex":[0.9998677,0.00001698335,0.00001411734,0.00002798068,0.00002644256,0.00004680237],"domain_scores_gemma":[0.999849,0.00002264204,0.00003653333,0.00002483988,0.00000627465,0.0000606192],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001441514,0.0009317437,0.0002723417,0.00009357455,0.00001203173,0.00007907877,0.00003209076,0.0002345551,0.9933602,0.00008473855,0.0001638872,0.003294248],"study_design_scores_gemma":[0.0001979065,0.004670238,0.002002072,0.000006067003,0.00002496119,0.0001908561,0.00001747066,0.001302252,0.9906682,0.00003962504,0.0008758701,0.000004502439],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973617,0.0005005022,0.001012195,0.0000606921,0.00003882254,0.0000398262,0.0001862876,0.0001549731,0.0006449028],"genre_scores_gemma":[0.9962074,0.0002577219,0.0009493789,0.00004022044,0.00001870344,0.00008883532,0.0005207471,0.00003306626,0.001884116],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001673631,"threshold_uncertainty_score":0.005598903,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4388621275","doi":"10.1159/000534303","title":"Second-Line Treatment after Failure of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy?","year":2023,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Internal medicine; Oncology; Bevacizumab; Atezolizumab; Nivolumab; Adverse effect; Immunotherapy; Gastroenterology; Cancer; Chemotherapy","authors":[{"name":"Sang Youn Hwang","is_ca":true},{"name":"Sangjune Laurence Lee","is_ca":true},{"name":"Hongqun Liu","is_ca":true},{"name":"Samuel S. Lee","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05778974049913274,"gpt":0.2666817629775639,"spread":0.2088920224784312,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00137705,0.000278324,0.001318834,0.0006521085,0.0001612137,0.0007324698,0.0004863683,0.0007472375,0.002765883],"category_scores_gemma":[0.00238083,0.0001049863,0.001064868,0.0005628198,0.0003443061,0.001158086,0.000251852,0.0008998266,0.0004552289],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000401986,"about_ca_system_score_gemma":0.001146478,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004949622,"about_ca_topic_score_gemma":0.002070296,"domain_scores_codex":[0.9994937,0.0001957065,0.0001200985,0.00006381172,0.000102468,0.00002422567],"domain_scores_gemma":[0.9989586,0.0006121729,0.0002642395,0.00001721409,0.0001207805,0.00002697379],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.0007001609,0.0001058401,0.00188162,0.08657248,0.0007895301,0.0005692189,0.0001695374,0.0004837383,0.00139768,0.002282468,0.02064423,0.8844035],"study_design_scores_gemma":[0.001052196,0.001946388,0.01538752,0.1359884,0.007219234,0.01062543,0.0009015604,0.001290527,0.003341553,0.008988222,0.813104,0.0001549453],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.0009917717,0.9963996,0.000200263,0.001559032,0.0002446107,0.00001198435,0.00003405652,0.000005550626,0.0005530845],"genre_scores_gemma":[0.0119538,0.9844245,0.0006579733,0.001832147,0.0006608772,0.00003162718,0.00008829078,0.000004457755,0.0003462468],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.002765883,"threshold_uncertainty_score":0.009252846,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4392015401","doi":"10.1159/000537966","title":"Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study","year":2024,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"National Cancer Institute; BeiGene","keywords":"Sorafenib; Hepatocellular carcinoma; Medicine; Quality of life (healthcare); Internal medicine; Oncology; Carcinoma","authors":[{"name":"Richard S. Finn","is_ca":false},{"name":"Masatoshi Kudo","is_ca":false},{"name":"Gisoo Barnes","is_ca":false},{"name":"Tim Meyer","is_ca":false},{"name":"Frédéric Boisserie","is_ca":false},{"name":"Ramil Abdrashitov","is_ca":false},{"name":"Yaxi Chen","is_ca":false},{"name":"Songzi Li","is_ca":false},{"name":"Andrew X. Zhu","is_ca":false},{"name":"Shukui Qin","is_ca":false},{"name":"Arndt Vogel","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1663480367441998,"gpt":0.3602734384689181,"spread":0.1939254017247184,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003130226,0.001043735,0.002249715,0.0002696927,0.000286801,0.0007699461,0.0007085621,0.0009342249,0.005174889],"category_scores_gemma":[0.002041827,0.0004230346,0.003447046,0.0003321711,0.0004612832,0.0006070304,0.0004254437,0.002516636,0.0007300454],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001039101,"about_ca_system_score_gemma":0.001791655,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001034574,"about_ca_topic_score_gemma":0.004464413,"domain_scores_codex":[0.9987063,0.0009421814,0.00005851002,0.0001024541,0.00009520982,0.00009532702],"domain_scores_gemma":[0.9984758,0.0003320824,0.0004887567,0.0001336185,0.0001283535,0.0004413631],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9278312,0.009563359,0.005206884,0.001523611,0.005453332,0.00008125103,0.00007194188,0.000942603,0.006950764,0.0001661268,0.003410547,0.03879845],"study_design_scores_gemma":[0.7799028,0.178545,0.0317938,0.0001829716,0.004106008,0.0001723856,0.0000548694,0.001514127,0.001036943,0.0002302809,0.002405652,0.00005524634],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9853586,0.006333047,0.0004575905,0.001281669,0.000334792,0.001500465,0.002374961,0.00008217133,0.002276765],"genre_scores_gemma":[0.9897951,0.002267245,0.0008814629,0.0008818666,0.0002781792,0.001474116,0.002396122,0.00002175307,0.002003947],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005174889,"threshold_uncertainty_score":0.01731169,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4392151488","doi":"10.1159/000537947","title":"Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT","year":2024,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Chugai Pharmaceutical; Genentech; Ipsen; Astellas Pharma; Eisai; Plexxikon; Seagen; Pfizer; NuCana; Incyte; BeiGene; Clovis Oncology; Les Laboratories Pierre Fabre; EA Pharma Co., Ltd.; Merck KGaA; Baxalta; Sirtex Medical; Cancer Research UK; Boston Scientific Corporation; Halozyme; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Celgene; Daiichi Sankyo Europe; National Cancer Institute; Servier; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Lenvatinib; Medicine; Sorafenib; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Oncology; Internal medicine; Randomized controlled trial; Overall survival; Radiology; Clinical trial; Phases of clinical research","authors":[{"name":"Richard S. Finn","is_ca":false},{"name":"Shukui Qin","is_ca":false},{"name":"Fabio Piscaglia","is_ca":false},{"name":"T.R. Jeffry Evans","is_ca":false},{"name":"Jennifer J. Knox","is_ca":true},{"name":"Carlos López","is_ca":false},{"name":"Zahra Ramji","is_ca":false},{"name":"Min Ren","is_ca":false},{"name":"Kalgi Mody","is_ca":false},{"name":"Arndt Vogel","is_ca":false},{"name":"Masatoshi Kudo","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04313391345594417,"gpt":0.2807608521821021,"spread":0.2376269387261579,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005168334,0.0006461744,0.001616377,0.0002907482,0.0001919109,0.0007962127,0.000448409,0.0005428567,0.001878499],"category_scores_gemma":[0.003484441,0.0002836861,0.001665759,0.0003143798,0.0005285731,0.0005342758,0.0003487949,0.001123319,0.0002860402],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005810795,"about_ca_system_score_gemma":0.0007965337,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002236802,"about_ca_topic_score_gemma":0.0008000455,"domain_scores_codex":[0.9974691,0.001825541,0.000158681,0.0002625398,0.0001719053,0.0001123323],"domain_scores_gemma":[0.9977942,0.0006865645,0.0009740301,0.0001744612,0.0001046825,0.0002660867],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9057417,0.002418202,0.03735014,0.0007319402,0.004919137,0.0000621913,0.00009991426,0.001129079,0.004089628,0.0001579815,0.001204912,0.04209528],"study_design_scores_gemma":[0.6918704,0.1459816,0.1434538,0.000151669,0.006765815,0.0004645396,0.0001022089,0.003649743,0.003550496,0.0006038673,0.003337473,0.00006837993],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924266,0.004224028,0.000489399,0.0004529337,0.00005685427,0.0007055494,0.0006833494,0.00004470998,0.0009164712],"genre_scores_gemma":[0.9960935,0.0007705831,0.0005517292,0.0003616097,0.0001200148,0.0007539087,0.0009982339,0.000007282206,0.0003431477],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005168334,"threshold_uncertainty_score":0.02733308,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4401410496","doi":"10.1159/000540290","title":"Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma","year":2024,"lang":"en","type":"article","venue":"Liver Cancer","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sudbury Regional Hospital","funders":"National Cancer Institute; University of California, San Francisco; University of Texas MD Anderson Cancer Center; Puma Biotechnology; Memorial Sloan-Kettering Cancer Center","keywords":"Neratinib; Medicine; Sunitinib; Everolimus; Axitinib; Tyrosine-kinase inhibitor; Nivolumab; Pembrolizumab; Internal medicine; Clinical endpoint; Oncology; Cancer; Immunotherapy; Clinical trial; Breast cancer","authors":[{"name":"Ghassan K. Abou‐Alfa","is_ca":false},{"name":"Tim Meyer","is_ca":false},{"name":"Richard Kinh Gian","is_ca":false},{"name":"Sarina A. Piha‐Paul","is_ca":false},{"name":"Joseph S. Light","is_ca":false},{"name":"Scott Sherrin","is_ca":false},{"name":"Amin Yaqubie","is_ca":false},{"name":"Alison Clemens O’Neill","is_ca":false},{"name":"James J. Harding","is_ca":false},{"name":"Raed Moh’d Taiseer Al-Rajabi","is_ca":false},{"name":"Crystal S. Denlinger","is_ca":false},{"name":"Pablo Cano","is_ca":true},{"name":"Albert Cornelius","is_ca":false},{"name":"Eileen M. O’Reilly","is_ca":false},{"name":"Daniel DiPrimeo","is_ca":false},{"name":"Lisa D. Eli","is_ca":false},{"name":"John D. Gordan","is_ca":false},{"name":"David B. Solit","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007036782436839323,"gpt":0.2275670107357827,"spread":0.2205302282989434,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008198872,0.0005534685,0.001468007,0.0002761874,0.0002688127,0.0005686372,0.0004774575,0.0004764594,0.001056355],"category_scores_gemma":[0.0007304671,0.0002570648,0.0008232017,0.0004051883,0.0002865398,0.000636126,0.000213311,0.0008414104,0.0002341838],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001072562,"about_ca_system_score_gemma":0.0008777764,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001120505,"about_ca_topic_score_gemma":0.005187131,"domain_scores_codex":[0.9997821,0.00006856822,0.00002962986,0.00004147941,0.00003199093,0.00004617725],"domain_scores_gemma":[0.9997303,0.00006101322,0.00006239153,0.00001885548,0.00002045018,0.0001068258],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.4186746,0.01229785,0.0921144,0.001687802,0.00309919,0.003047343,0.0005330373,0.00922303,0.1050273,0.0004516794,0.007970397,0.3458733],"study_design_scores_gemma":[0.1899485,0.4352432,0.2917655,0.0002941832,0.004980878,0.006810992,0.0006243748,0.01208172,0.03680663,0.0005476847,0.02066749,0.0002288024],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9933675,0.003989021,0.0001317286,0.0003089451,0.0000563776,0.0001483441,0.0002260948,0.00003352798,0.001738435],"genre_scores_gemma":[0.9976828,0.0009965658,0.0002044248,0.0002411487,0.00004325281,0.00007646945,0.0003866033,0.000005446645,0.0003632726],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001468007,"threshold_uncertainty_score":0.007781982,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417466987","doi":"10.1159/000549955","title":"Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis","year":2025,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Durvalumab; Tremelimumab; Hepatocellular carcinoma; Phases of clinical research; Ramucirumab; Chemoradiotherapy; Carcinoma","authors":[{"name":"Stephen L. Chan","is_ca":false},{"name":"Masatoshi Kudo","is_ca":false},{"name":"Bruno Sangro","is_ca":false},{"name":"Robin Kate Kelley","is_ca":false},{"name":"Jee Hyun Kim","is_ca":false},{"name":"Binh V. Pham","is_ca":false},{"name":"Jung Yong Hong","is_ca":false},{"name":"Dirk‐Thomas Waldschmidt","is_ca":false},{"name":"Donatella Marino","is_ca":false},{"name":"Joycelyn Jie Xin Lee","is_ca":false},{"name":"René Gerolami","is_ca":false},{"name":"Adam M. Burgoyne","is_ca":false},{"name":"Qiao Li","is_ca":true},{"name":"Hitomi Nakamura","is_ca":false},{"name":"Peng Sun","is_ca":false},{"name":"Boris Baur","is_ca":false},{"name":"Lorenza Rimassa","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09119294205123218,"gpt":0.3126555805677392,"spread":0.221462638516507,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005940027,0.0008711208,0.001346453,0.0002489739,0.0004713473,0.00101483,0.0007901682,0.0009176544,0.005334135],"category_scores_gemma":[0.004673198,0.0005079594,0.001754497,0.0002827767,0.0004679305,0.000762936,0.0005246711,0.002327075,0.00125289],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006858178,"about_ca_system_score_gemma":0.00159206,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006284926,"about_ca_topic_score_gemma":0.002552075,"domain_scores_codex":[0.9981576,0.001125214,0.00009232961,0.0002044926,0.000267985,0.0001524819],"domain_scores_gemma":[0.9954918,0.001070414,0.001396525,0.0004476029,0.0005778007,0.001015855],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.846194,0.01023066,0.03349121,0.00160147,0.005137609,0.0002077846,0.0002670246,0.001104244,0.01663105,0.0003992069,0.01633416,0.06840156],"study_design_scores_gemma":[0.6242553,0.2211181,0.1234829,0.0002315886,0.005422343,0.000753388,0.0001251854,0.001379706,0.005916228,0.0006762724,0.01653619,0.0001029178],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9606959,0.00689229,0.001655548,0.001568145,0.0002190201,0.004219023,0.0163818,0.0003676711,0.008000668],"genre_scores_gemma":[0.974833,0.001411574,0.002644035,0.001664802,0.0002206253,0.003746109,0.01278128,0.00006195953,0.002636529],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005940027,"threshold_uncertainty_score":0.03141421,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3139664658","doi":"10.36255/exonpublications.livercancer.2021.ch4","title":"Gross Dissection of Liver for Hepatocellular Carcinoma Using AJCC Cancer Staging Manual 8th Edition: Anatomical and Practical Considerations","year":2021,"lang":"en","type":"book-chapter","venue":"Liver Cancer","topic":"Congenital Heart Disease Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Stollery Children's Hospital; University of Alberta; University of Alberta Hospital","funders":"","keywords":"Dissection (medical); Hepatocellular carcinoma; Medicine; Liver cancer; Cancer; General surgery; Terminology; Resection; Pathology; Radiology; Surgery; Internal medicine","authors":[{"name":"Marla Beach","is_ca":true},{"name":"Laura Henao Caviedes","is_ca":true},{"name":"Consolato Sergi","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07437325643932621,"gpt":0.348629559974269,"spread":0.2742563035349428,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004868897,0.0007731948,0.0004050489,0.001443468,0.0005398711,0.0008171601,0.0006170571,0.0006310074,0.02683994],"category_scores_gemma":[0.0007540449,0.0003109601,0.0003386564,0.001034463,0.0005045266,0.001068197,0.0005693126,0.001879054,0.02247539],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004853561,"about_ca_system_score_gemma":0.001046458,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002358545,"about_ca_topic_score_gemma":0.01056228,"domain_scores_codex":[0.9997808,0.00003259707,0.00002044082,0.00002035913,0.0001351088,0.00001051589],"domain_scores_gemma":[0.9996976,0.0001181793,0.00002422303,0.00001571185,0.0001216204,0.00002265933],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001226237,0.00003309079,0.0002978822,0.0004294469,0.00000369815,0.0002540872,0.000334932,0.0003380363,0.001107174,0.0107974,0.6793328,0.3070591],"study_design_scores_gemma":[0.000001371155,0.00001458998,0.0007860342,0.0002590209,0.000002334065,0.001293218,0.00005770085,0.0001144526,0.0001599081,0.003691086,0.993612,0.000008336707],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"methods","genre_scores_codex":[0.002656921,0.1122468,0.05189447,0.01793654,0.01277529,0.000783744,0.003527789,0.002150103,0.7960283],"genre_scores_gemma":[0.01029837,0.1048865,0.1408793,0.009206668,0.003713705,0.000535441,0.00435255,0.001196103,0.7249314],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.02683994,"threshold_uncertainty_score":0.08978856,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4249856389","doi":"10.36255/exonpublications.livercancer.2021.pr","title":"Preface","year":2021,"lang":"en","type":"book-chapter","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; Stollery Children's Hospital","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Etiology; Fatty liver; Cancer; Liver cancer; Disease; Pathology; Internal medicine","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.09531691578801603,"gpt":0.261330717019093,"spread":0.166013801231077,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004848079,0.0008510367,0.0006496183,0.001441566,0.00161432,0.00313625,0.0009911333,0.001083711,0.3835712],"category_scores_gemma":[0.002721621,0.0003072939,0.000510085,0.001109406,0.000506882,0.002529351,0.001528017,0.002675901,0.2713969],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00124992,"about_ca_system_score_gemma":0.001120166,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001676233,"about_ca_topic_score_gemma":0.002484919,"domain_scores_codex":[0.9995903,0.00004963553,0.00002114548,0.00008002054,0.0002219257,0.00003706771],"domain_scores_gemma":[0.9986916,0.0002344331,0.00005049618,0.00009372465,0.0006951067,0.0002346402],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001287193,0.00001766555,0.00006345665,0.00008873663,0.00000125676,0.0000617918,0.0000923495,0.00005575613,0.0001573096,0.005162598,0.9526302,0.04165597],"study_design_scores_gemma":[0.000001307445,0.000006454063,0.00009519189,0.00006353641,5.829039e-7,0.00009755967,0.00004220828,0.00002077792,0.00003688701,0.0009788891,0.9986545,0.000001970429],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.001028787,0.01235888,0.003819509,0.01414222,0.06789108,0.0002714368,0.002797422,0.000956588,0.8967339],"genre_scores_gemma":[0.002261499,0.004570603,0.001610855,0.003170079,0.00717049,0.00008162633,0.0018401,0.0003734415,0.9789214],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.3835712,"threshold_uncertainty_score":0,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2131550821","doi":"10.1007/978-1-4020-9804-8_5","title":"Selection of Patients for Resection of Hepatic Colorectal Metastases: 18F-Fluorodeoxyglucose/Positron Emission Tomography","year":2009,"lang":"en","type":"book-chapter","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Positron emission tomography; Colorectal cancer; Radiology; Fluorodeoxyglucose; Stage (stratigraphy); Cancer; Internal medicine","authors":[{"name":"Rebecca A. Auer","is_ca":true},{"name":"Yuman Fong","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03014802831968243,"gpt":0.2518629784872493,"spread":0.2217149501675669,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000207681,0.0002381016,0.0003161556,0.0003190351,0.0001387892,0.0002541991,0.0001459118,0.0002134217,0.002949288],"category_scores_gemma":[0.0005265943,0.00008033193,0.0001393775,0.0002553787,0.0001009551,0.0001553746,0.000102329,0.0002585161,0.001184076],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001519422,"about_ca_system_score_gemma":0.0002659015,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007229366,"about_ca_topic_score_gemma":0.002383957,"domain_scores_codex":[0.9999557,0.000013844,0.000004323197,0.000005090824,0.00001543526,0.000005733662],"domain_scores_gemma":[0.9999332,0.00003076457,0.000008538369,0.000003361598,0.000009974409,0.00001400921],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.000523637,0.0001195389,0.1137569,0.0001968295,0.00003386321,0.00521435,0.0002421269,0.001261034,0.01223872,0.002680493,0.07579494,0.7879376],"study_design_scores_gemma":[0.000193574,0.0011548,0.4215528,0.000689259,0.0001414868,0.08725201,0.001447592,0.005755785,0.01339392,0.01390615,0.454365,0.0001477374],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4615104,0.09924823,0.1017163,0.03034396,0.004517909,0.0007765634,0.003742007,0.0009435984,0.297201],"genre_scores_gemma":[0.7910021,0.04354179,0.08162378,0.004829286,0.00240834,0.0003498055,0.003539267,0.0002630324,0.07244261],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002949288,"threshold_uncertainty_score":0.009866357,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4404467870","doi":"10.1159/000542146","title":"Acknowledgement to Reviewers","year":2024,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Acknowledgement; Medicine; Computer science; Computer security","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.09618991736786028,"gpt":0.3242552020021041,"spread":0.2280652846342438,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.02453146,0.002549548,0.002399869,0.007014452,0.004309461,0.01776468,0.005314993,0.00738649,0.2363347],"category_scores_gemma":[0.2370569,0.0009840984,0.001690259,0.00383855,0.002552795,0.01059428,0.008561293,0.009297763,0.158507],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.007551532,"about_ca_system_score_gemma":0.01773302,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002661914,"about_ca_topic_score_gemma":0.00348593,"domain_scores_codex":[0.9633359,0.01114994,0.004574756,0.004903978,0.01374999,0.002285469],"domain_scores_gemma":[0.719859,0.0280475,0.01078885,0.01242351,0.2077535,0.02112759],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001915812,0.000004744586,0.0000515579,0.0001643051,0.000004656032,0.0000541505,0.0001307087,0.00001268565,0.00003614532,0.0009256027,0.9883389,0.01025736],"study_design_scores_gemma":[0.000009854441,0.000006817346,0.00008147721,0.0003154743,0.000005906773,0.0001378075,0.000250234,0.00002341011,0.00003698972,0.0008004326,0.9983189,0.00001265975],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"other","genre_scores_codex":[0.0003042528,0.01219767,0.002865064,0.2279861,0.7093457,0.0005496513,0.001657121,0.001339465,0.04375491],"genre_scores_gemma":[0.01024092,0.01817772,0.006931029,0.2039205,0.3265184,0.002214993,0.003648573,0.003519402,0.4248284],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.7636653,"threshold_uncertainty_score":0.7906184,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4414450104","doi":"10.1159/000548606","title":"Surrogate Endpoints for Overall Survival in Advanced Hepatocelluar Carcinoma in the Era of Immunotherapy: A Trial Level Meta-Analysis","year":2025,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Surrogate endpoint; Overall survival; Clinical endpoint; Progression-free survival; Endpoint Determination; Survival analysis","authors":[{"name":"Yacob Saleh","is_ca":true},{"name":"Zeynep Baskurt","is_ca":true},{"name":"Abdul Rehman Farooq","is_ca":true},{"name":"Rachel Goodwin","is_ca":true},{"name":"Jennifer J. Knox","is_ca":true},{"name":"Grainne O ́Kane","is_ca":false},{"name":"Eric X. Chen","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1833565736483253,"gpt":0.3373217047050122,"spread":0.1539651310566869,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.02705481,0.003209655,0.01712846,0.003867893,0.0005018062,0.003901344,0.002173994,0.002456012,0.003569762],"category_scores_gemma":[0.037625,0.001235956,0.07350503,0.00437116,0.0007260788,0.002029925,0.001716573,0.003228796,0.0004243301],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002025928,"about_ca_system_score_gemma":0.001773174,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002863837,"about_ca_topic_score_gemma":0.004299376,"domain_scores_codex":[0.978208,0.01533653,0.002946803,0.001817228,0.001227461,0.0004639845],"domain_scores_gemma":[0.9737593,0.02022242,0.003175202,0.001349747,0.001120748,0.0003726462],"domain_codex":null,"domain_gemma":"methods","domain_candidate":"methods","domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.005989912,0.00002575024,0.003066708,0.03448297,0.9511555,0.0000601407,0.00002230241,0.001059202,0.0001756995,0.00009885971,0.000290691,0.003572218],"study_design_scores_gemma":[0.001192195,0.0002522912,0.001747396,0.001658236,0.9937096,0.00003666612,0.00001162761,0.0005691836,0.00007587796,0.0002486858,0.0004843851,0.00001385354],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.03466049,0.9543215,0.005837568,0.0008185065,0.0006403061,0.000713571,0.001772165,0.0001585656,0.001077341],"genre_scores_gemma":[0.7874979,0.1952313,0.007515875,0.002081085,0.00082977,0.002776512,0.002763544,0.000161493,0.001142488],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.9967903,"threshold_uncertainty_score":0.1430812,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2106822989","doi":"10.1007/978-1-4020-9804-8_7","title":"Intraoperative Magnetic Resonance Imaging for Radiofrequency Ablation of Hepatic Tumors","year":2009,"lang":"en","type":"book-chapter","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Debulking; Radiofrequency ablation; Magnetic resonance imaging; Radiology; Ablation; Interventional magnetic resonance imaging; Cancer","authors":[{"name":"Oliver F. Bathe","is_ca":true},{"name":"Houman Mahallati","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03694870924908961,"gpt":0.2508398812122156,"spread":0.213891171963126,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002591079,0.000627475,0.0003976716,0.0007324402,0.0001153523,0.000421328,0.0005611209,0.0006146875,0.006883109],"category_scores_gemma":[0.0003758128,0.0001894641,0.0002482999,0.0004066704,0.0002901288,0.000883188,0.0003131136,0.001183343,0.00389394],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002003223,"about_ca_system_score_gemma":0.0002940387,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004179496,"about_ca_topic_score_gemma":0.001644982,"domain_scores_codex":[0.9999504,0.00001049903,0.000003971642,0.000005981248,0.00002557707,0.000003554],"domain_scores_gemma":[0.9998649,0.00009560395,0.000008868179,0.00000670847,0.00001645689,0.000007422314],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.00005029573,0.00006207,0.0003346982,0.0008329081,0.00001789869,0.001303721,0.0002004343,0.0007853947,0.01028959,0.01305555,0.0894654,0.8836022],"study_design_scores_gemma":[0.00001562646,0.0001063628,0.001839187,0.00083695,0.00003163637,0.02447423,0.00006445208,0.001139937,0.004714185,0.01270257,0.9540347,0.00004010326],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.006538263,0.6049449,0.07319394,0.004732227,0.005491839,0.0001400381,0.0002267188,0.0006881716,0.3040438],"genre_scores_gemma":[0.04327371,0.4770166,0.1089816,0.004732633,0.00715258,0.000262792,0.0004595973,0.0004980282,0.3576224],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.006883109,"threshold_uncertainty_score":0.02302629,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}